|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
Compact Navigation System for CT-guided Needle Interventions
|
1UT1CA224886-01A1
|
$149,927
|
|
TSE, TSZ HO
|
3T TECHNOLOGIES, LLC
|
|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
|
1R44CA224718-01A1
|
$159,365
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Affinity Purification of Biologics with Mimetope Peptides
|
1R43CA228945-01
|
$217,898
|
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
The Madrina Network Web Portal
|
3R44CA177037-03S1
|
$34,313
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
Image-guided ultrasound ablation for precision targeting of prostate cancer
|
1R01CA230323-01
|
$580,217
|
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
IeDEA West Africa Renewal 3
|
5U01AI069919-13
|
$225,000
|
|
DABIS, FRANCOIS
|
ADERA
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
Distance Education to Engage Alaskan Community Health Aides in Cancer Control
|
5R25CA186882-05
|
$135,579
|
|
CUEVA, MELANY
|
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Womens Interagency HIV Study (WIHS-V)
|
3U01AI035004-25S1
|
$144,370
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Central Africa International Epidemiologic Database to Evaluate AIDS
|
5U01AI096299-09
|
$260,000
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-05
|
$701,988
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis
|
1R01CA222358-01A1
|
$635,306
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Nutritionally Driven Sporadic Intestinal Tumors: Impact on Stem Cells
|
1R01CA229216-01
|
$493,238
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
5U01CA078527-21
|
$581,591
|
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center
|
5P20CA210284-02
|
$247,982
|
|
CASTLE, PHILIP
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-16
|
$2,028,990
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The role of macroH2A variants in cancer and senescence
|
5R01CA155232-08
|
$382,013
|
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-05
|
$346,525
|
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
5F30CA210539-03
|
$44,524
|
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Synergistic co-targeting of pro-apoptotic BAX and anti-apoptotic BCL-XL in cancer
|
1F31CA236434-01
|
$44,524
|
|
LOPEZ-ARROYO, ANDREA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
|
1R01CA226861-01
|
$382,013
|
|
MACIAN, FERNANDO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Training of Surgeons for Studies of the Tumor Microenvironment
|
5T32CA200561-04
|
$264,583
|
|
MICHLER, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Design and Development of Inhibitors of Methionine Adenosyltransferase for Cancer Treatment
|
1F32CA225149-01A1
|
$58,654
|
|
NILAND, COURTNEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
|
5R01CA218429-02
|
$1,347,851
|
|
ROHAN, THOMAS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
RCT of An Internet Cessation Program Plus Online Social Network for HIV + Smokers
|
5R01CA192954-05
|
$626,669
|
|
SHUTER, JONATHAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Optimization of Non-Ablative Focused Ultrasound Therapy for Tumor Immunity
|
5F30CA200411-05
|
$49,524
|
|
SKALINA, KARIN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Methylome characterization of bronchial epithelial projenitor cells
|
5R21CA209436-02
|
$180,130
|
|
SPIVACK, SIMON
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Next Generation of HPV and Cervical Cancer Research in HIV+ Women
|
1R01CA230331-01
|
$670,295
|
|
STRICKLER, HOWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
Total relevant funding to Agent Orange/Dioxin Related for this search: $805,506
|